Litigation Details for AMGEN INC. v. PRICE (D.C. 2017)
✉ Email this page to a colleague
AMGEN INC. v. PRICE (D.C. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-05-25 |
| Court | District Court, District of Columbia | Date Terminated | |
| Cause | 05:0706 Judicial Review of Agency Actions | Assigned To | Randolph Daniel Moss |
| Jury Demand | None | Referred To | |
| Patents | 6,011,068 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AMGEN INC. v. PRICE
The small molecule drug covered by the patent cited in this case is ⤷ Sign Up .
Details for AMGEN INC. v. PRICE (D.C. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-05-25 | 1 | NSiPAR, U.S. Patent No. 6,011,068 (the ‘068 Patent), is due to expire on March 8, 2018. As a result, the … of 33 existing patent rights 21 U.S.C. § 355a(b)(2), (c)(2). One ofthe key patents covering Sf€NSiPAR…exclusivity and patent-related protections After any such periods of exclusivity and patent protections expire…and patent protection automatically applies Id. at §§ 355a(b)(l), (c)(l) (exclusivities and patent protection…of’ the underlying patent exclusivity ld. §§ 355a(b)(2), (c)(2). Because a key patent covering SENSIPAR | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
